BCG and COX-2 Inhibitor Combination for Immune Restoration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapy approaches, including those using Bacillus Calmette Guerin (BCG), face limitations in effectively enhancing cell-mediated immunity due to the detrimental effects of prostaglandin E2 (PGE2) on macrophage activity and CD8+ T cell responses, leading to inadequate antigen presentation and cytokine production, particularly in cancer and infectious diseases.
Innovation Solution
Combining BCG with anti-COX-2 selective molecules or COX-2 preferential NSAIDs to inhibit PGE2 synthesis, thereby enhancing macrophage activity, antigen presentation, and CD8+ T cell responses, promoting a balanced Th1 immune phenotype and improving cell-mediated immunity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If BCG is administered to enhance cell-mediated immunity, then macrophage activation and cytokine production are improved, but PGE2 synthesis increases which suppresses macrophage activity and CD8+ T cell responses
Solution Approach 1:
The patent applies this principle by using the harmful PGE2 byproduct of BCG administration as a target for intervention. Celecoxib, a COX-2 inhibitor, is introduced to specifically block PGE2 synthesis, converting the harmful effect into a manageable parameter. The combination therapy transforms the originally harmful PGE2-mediated suppression into an opportunity to enhance immune response by eliminating the suppressive pathway while preserving the beneficial BCG-induced macrophage activation.
Solution Approach 2:
The patent introduces celecoxib as an intermediary substance that mediates between BCG administration and the immune response. Celecoxib acts as a pharmacological mediator that selectively inhibits the COX-2 enzyme pathway, thereby blocking PGE2 production without interfering with the direct immunostimulatory effects of BCG on macrophages and T cells. This intermediary approach allows simultaneous administration of BCG and celecoxib to achieve synergistic immune enhancement.
2Productivity
If BCG stimulates macrophage activation and antigen presentation, then immune response is enhanced, but PGE2-mediated suppression reduces CD8+ T cell responses and cytokine production
Solution Approach 1:
The patent converts the harmful PGE2-mediated suppression of CD8+ T cell responses into a beneficial therapeutic opportunity. By administering celecoxib to specifically inhibit COX-2 and block PGE2 synthesis, the patent eliminates the suppressive effect on CD8+ T cells while preserving the enhanced antigen presentation capability induced by BCG. This results in a dual-benefit scenario where both macrophage function and T cell response are optimized.
3Productivity
If BCG induces inflammatory response to activate immune system, then macrophage recruitment is improved, but excessive inflammation suppresses effective immune function
Solution Approach 1:
The patent applies local quality by selectively targeting the PGE2 synthesis pathway in inflamed tissues where COX-2 is upregulated. Celecoxib, as a selective COX-2 inhibitor, acts locally at sites of inflammation to suppress excessive PGE2 production without systemically suppressing the beneficial inflammatory response induced by BCG. This localized intervention allows macrophage recruitment to proceed while preventing PGE2-mediated immunosuppression in the target tissues.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination restores effective cell-mediated responses, enhancing antigen presentation, nitric oxide production, and CD8+ T cell activity, leading to improved immune function against neoplastic and infectious challenges, including cancer and infectious diseases.
Implementation Method 1
anti-COX-2 selective molecules and/or COX-2 preferential FANS...show strong selective inhibiting power towards the inducible form of COX enzyme (indicated as COX-2)...inhibit PGE2 synthesis
Implementation Method 2
BCG exalts the cell-mediated response...determining lymphocytes and macrophages recruitment...great production of cytokines as IFN-γ and IL-2
Implementation Method 3
BCG exalts cell-mediated response...by the way of a great synthesis of nitrogen monoxide (NO)...enhancing antigen presentation, nitric oxide production
Implementation Method 4
PGE2...depresses macrophage phagocytosis, the ability of presentation of the antigen...detrimental effects of prostaglandin E2 (PGE2) on macrophage activity
Data Source
Figure 1
Figure 2a~2b
Figure 2c~2d
AI summary
The combination of Bacillus Calmette Guerin (BCG) with anti-COX-2 selective molecules and/or COX-2 preferential FANS for the treatment of pathologies related to the loss of macrophages functions and deficiencies of cell-mediated immunity.